PIK3CA and chordoma: However, despite chordomas being immunoreactive for the activated form of EGFR (p‐EGFR), they do not harbour EGFR mutations and only infrequently other currently potentially tractable targets, such as PIK3CA mutations 18, 23, 24, 25.